Premium
Phase‐Change Materials Based Nanoparticles for Controlled Hypoxia Modulation and Enhanced Phototherapy
Author(s) -
Zhang Shichao,
Li Qinzhe,
Yang Nan,
Shi Yunhao,
Ge Wei,
Wang Wenjun,
Huang Wei,
Song Xuejiao,
Dong Xiaochen
Publication year - 2019
Publication title -
advanced functional materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.069
H-Index - 322
eISSN - 1616-3028
pISSN - 1616-301X
DOI - 10.1002/adfm.201906805
Subject(s) - materials science , photosensitizer , tumor hypoxia , photothermal therapy , nanoparticle , photodynamic therapy , in vivo , hypoxia (environmental) , controlled release , photodegradation , cancer research , biophysics , oxygen , radiation therapy , nanotechnology , medicine , chemistry , photocatalysis , photochemistry , biochemistry , biology , microbiology and biotechnology , organic chemistry , catalysis
Tumor hypoxia strengthens tumor resistance to different therapies especially oxygen involved strategies, such as photodynamic therapy (PDT). Herein, the thermal responsive phase change materials (PCM) are utilized to coencapsulate ultrasmall manganese dioxide (sMnO 2 ) and organic photosensitizer IR780 to obtain IR780‐sMnO 2 ‐PCM nanoparticles for controlled tumor hypoxia modulation and enhanced phototherapy. The thermal responsive protective PCM layer can not only prevent IR780 from photodegradation, but also immediately release sMnO 2 to decompose endogenous H 2 O 2 and generate enough oxygen for PDT under laser irradiation. Owing to the efficient accumulation of IR780‐sMnO 2 ‐PCM nanoparticles in tumor under intravenous injection as revealed by both florescence imaging and photoacoustic imaging, the tumor hypoxia is greatly relieved. Furthermore, in vivo combined photothermal therapy (PTT) and PDT, IR780‐sMnO 2 ‐PCM nanoparticles, compared to IR780‐PCM nanoparticles, exhibit better performance in inhibiting tumor growth. The results highlight the promise of IR780‐sMnO 2 ‐PCM in controlled modulation of tumor hypoxia to overcome current limitations of cancer therapies.